Response: upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase
Articles > Article · 2017
Authors: Güray SAYDAM
Expert Opinion on Pharmacotherapy, International, WoS, 2017, vol 18, pp 327-328
DOI: 10.1080/14656566.2017.1282701
Summary
Dear Editor,We have read the comments by Dr. Emre Eşkazan on our recent paper [1] reporting the results of a multicenter study from Turkey which evaluated the efficacy and safety of nilotinib 300 m...